Formation of antinuclear and double strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease

Beigel, Florian; Schnitzler, F; Göke, B.; Ochsenkühn, Thomas; Brand, Stephan

doi:10.1055/s-0030-1263682

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Anti-TNF-α agents may also induce of autoimmunity, including formation of antinuclear, anti-DNA, and anti-cardiolipin antibodies, among others. 9 There is also a rare lupus-like syndrome associated with this therapy. For example, sixteen new cases of systemic lupus M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT erythematosus were reported after etanercept treatment to the FDA over a three-year period 91 but it is difficult to differentiate drug-induced from a primary diagnosis of lupus.…”

Section: Demyelinating Disease and Other Neuropathiesmentioning

confidence: 99%

Anti–tumor necrosis factor-α therapy in uveitis

Cordero‐Coma

Sobrin

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

Section: Demyelinating Disease and Other Neuropathiesmentioning

confidence: 99%

Anti–tumor necrosis factor-α therapy in uveitis

Cordero‐Coma

Sobrin

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

“…36,37 Lupus-like syndrome (LLS) can occur with anti-TNF and can present with cutaneous manifestations, such as butterfly rash, The presence of double-stranded DNA antibody levels $9 U/mL, but not antinuclear antibody titers $1:240, seems to be more specific for diagnosis in a patient with a compatible clinical picture. 38 LLS usually reverses after anti-TNF discontinuation, and it does not necessarily recur on rechallenge with a second anti-TNF. In a cohort from the United States, of 13 patients with IFXinduced LLS, 8 were retreated with a second anti-TNF, 1 discontinued therapy despite no recurrence of LLS because of fear of side effects, and 5 remained well with no recurrence of LLS after a median of 5-month therapy (range, 2-6 months).…”

Section: Adverse Skin Reactions Induced By Anti-tnf Therapymentioning

confidence: 99%

Skin Side Effects of Inflammatory Bowel Disease Therapy

Torres

Buche

Delaporte

et al. 2013

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Skin manifestations are common in patients suffering from inflammatory bowel disease (IBD) and can be associated with the disease itself, with nutritional deficiencies, or with therapy. All drugs currently used for treating IBD have the potential to cause dermatologic manifestations that can have a wide range of clinical presentations, from mild drug eruptions to potentially life-threatening immune-mediated reactions. The wider use of thiopurines and anti-tumor necrosis factor in the past years has led to the recognition of 2 more skin complications of IBD therapy: the potentially disfiguring non-melanoma skin cancer associated with the current or past use of thiopurines and the paradoxical new onset or exacerbation of anti-tumor necrosis factor-associated psoriasis. Despite being rare, these complications can be severe and lead to therapy discontinuation, and therefore, gastroenterologists need to become familiar with their epidemiology, diagnosis, and management. Herein, we reviewed the skin side effects of IBD therapy, specially focusing in thiopurines and anti-tumor necrosis factor therapy and in the recently described skin cancer and psoriasis, and we tried to advance some practical algorithms that can provide some help to the clinicians dealing with these complications in their day-by-day practice.

show abstract

“…Autoimmune reactions during therapy, including the development of a lupus-like syndrome [13] or even cases of autoimmune-like hepatitis [14], have been described. The mechanism of action, besides the direct neutralization of soluble TNF-alpha, includes a proapoptotic effect on lymphocytes and decreased GM-CSF production by T cells [15].…”

Section: Introductionmentioning

confidence: 99%